Novartis
CHMP recommends marketing authorisation for Novartis’ Kesimpta
February 1, 2021Sales and Marketing Novartis, multiple sclerosis
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorisation of Novartis’ Kesimpta (ofatumumab) for …
Novartis’ Cosentyx available on NHS in Scotland
January 19, 2021Manufacturing and Production Novartis
Novartis has announced that Cosentyx (secukinumab) 150mg is available in Scotland on the NHS, licensed for adults with active non-radiographic …
Novartis’ ligelizumab granted FDA Breakthrough Therapy Designation
January 14, 2021FDA, Novartis
The FDA has granted Novartis’ ligelizumab Breakthrough Therapy Designation for the treatment of chronic spontaneous urticaria (CSU) in patients who …
Novartis and BeiGene join forces to develop cancer drug tislelizumab
January 12, 2021Manufacturing and Production BeiGene, Cancer, Novartis
Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene Ltd in major markets outside of China, accelerating …
Novartis acquires Cadent Therapeutics in potential $770 million deal
December 17, 2020Sales and Marketing Cadent, Novartis, acquisition
Novartis has sealed an agreement with Cadent Therapeutics to acquire the firm in a deal worth up to $770 million, …
NICE recommends Novartis’ Beovu for wet age-related macular degeneration
December 16, 2020Research and Development NICE, Novartis, wet AMD Beovu
NICE has published its final appraisal of Novartis’ Beovu (brolucizumab), recommending that the drug be made available via the NHS …
FDA panel backs Novartis’ Entresto for different form of heart disease
December 16, 2020Research and Development FDA, Novartis, heart failure
Novartis’ heart failure drug Entresto has received recommendation from the FDA’s Cardiovascular and Renal Drugs Advisory Committee for use in …
Novartis and Incyte’s ruxolitinib fails to show benefit in COVID-19 at Phase 3
December 14, 2020Research and Development, Sales and Marketing COVID-19, Incyte, Novartis
Novartis has unveiled that its JAK 1/2 tyrosine kinase inhibitor ruxolitinib fell short of its main efficacy goal in the …
NICE backs Novartis’ Aimovig for prevention of episodic and chronic migraine
December 11, 2020Medical Communications, Sales and Marketing Aimovig, NICE, Novartis, migraine
NICE has announced its decision to recommended Novartis’ Aimovig (erenumab) for the prevention of migraine, including both episodic and chronic …
Novartis’ Kisqali delays need for chemo by over 4 years in post-menopausal HR+HER2- metastatic breast cancer
December 9, 2020Research and Development Kisqali, Novartis, breast cancer
Novartis has lifted the curtain on updated Phase 3 data for Kisqali (ribociclib) in the treatment of hormone receptor positive, …
Novartis unveils new multi-trial data for CAR-T therapy Kymriah in advanced lymphoma
December 7, 2020Research and Development, Sales and Marketing CAR-T, Kymriah, Novartis
Novartis has taken the opportunity at the 2020 American Society of Hematology Annual Meeting & Exposition (ASH) to unveil promising …
Jakafi outperforms best available therapy in steroid-refractory/dependent chronic graft-versus-host disease
December 7, 2020Research and Development, Sales and Marketing Incyte, Jakafi, Novartis
The first Phase 3 findings have been revealed for Jakafi (ruxolitinib) in the treatment of steroid-refractory or steroid-dependent chronic graft-versus-host disease …
Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis
October 15, 2020Sales and Marketing Mayzent, Novartis, Scotland
Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of secondary progressive multiple sclerosis (SPMS) …
Novartis unveils strong Phase 3 efficacy for one-time therapy Zolgensma in paediatric spinal muscular atrophy
October 1, 2020Research and Development Novartis, Zolgensma, spinal muscular atrophy
Novartis has lifted the curtain on new Phase 3 data from an ongoing trial of 33 participants on the efficacy …
Piqray and Faslodex combo extends survival in HR+/HER2-, PIK3CA+ advanced breast cancer at ESMO 2020
September 21, 2020Research and Development, Sales and Marketing Cancer, ESMO 2020, Novartis, pharma
New data has been unveiled for the combination of Novartis’ Piqray (alpelisib) with AstraZeneca’s Faslodex (fulvestrant) in the treatment of …
